Ahmedabad, Nov 03: Epigral Limited, one of India’s integrated chemical manufacturers, today announced its financial results for the quarter ended September 30, 2026. The company posted a growth of 26% in PAT for Q2FY27 at ₹ 64 Cr, as compared to ₹ 51 Cr in Q2FY26. The quarterly revenue rose by 28% to ₹ 752 Cr as against ₹ 589 Cr recorded in the same quarter of last fiscal.
The key performance highlights:
Q2FY27 Key Financial Highlights:
-
YoY sales volume grew by 6%, despite the challenging and volatile market conditions
-
Revenue grew by 28% to ₹ 752 Crore on account of volume growth and majorly due to improved realisations
-
Derivatives & Specialty business contributed 57% of revenue vs 50% in Q2FY26
-
EBITDA stood at ₹ 136 Crore vs ₹ 132 Crore. EBITDA margin was muted on account of high cost of raw materials and stood at 18%
-
PAT grew by 26% to ₹ 64 Crore vs ₹ 51 Cr
H1FY27 Key Financial Highlights:
-
Revenue rose by 21% to ₹1,461 Crore, compared to ₹1,204 Crore, despite geopolitical tensions, volatile price movements, and off season for few of our products
-
EBITDA stood at ₹ 315 Crore vs ₹ 296 Crore. EBITDA margin was maintained at 22%
-
PAT rose by 25% to ₹ 164 Crore vs ₹ 131 Crore
Commenting on the results, Maulik Patel, Chairman and Managing Director, Epigral Limited, said:
“Despite a challenging operating environment in Q2FY27, we achieved revenue growth of 28%, driven by volume growth and improved realisations. Elevated raw material prices had its impact on EBITDA margins; however, our H1FY27 performance remained resilient, with revenue growth of 21% and an EBITDA margin of 22%. With the second half of the fiscal traditionally delivering stronger performance than the first, we maintain positive outlook for H2FY27.”
“Fueled by India's robust demand growth, we are executing our expansion plans on schedule. The CPVC and ECH expansions are in their final stages with trial runs underway; both plants are expected to commission in a quarter’s time. Meanwhile, our Epoxy Resin & Formulation and MPP projects are progressing as planned. The Revenue contribution from Derivatives & Specialty business stood at 57% and will expand further with these projects”.
Epigral remains focused on strengthening its integrated manufacturing ecosystem, broadening its portfolio of high-value chemical products, and creating long-term value for all stakeholders” Mr Patel added.
H1FY27 Strategic Highlights:
-
Epigral spent ₹ 88 Crore on capex in H1FY27
-
Epigral’s board approved capex in below two projects, which are expected to commission by H2FY28
-
Epoxy Resin & Formulations plant with capacity of 1,25,000 TPA
-
Multi-Purpose Plant (MPP) downstream for Epichlorohydrin (ECH) and Chlorotoluene Value Chain
-
Epigral has set up pilot plant for Epoxy Resin & Formulations and MPP to optimise manufacturing process, validate product quality and facilitate customer approvals ahead of commercial scale production
-
Capex of enhancing CPVC Resin, ECH and Wind Solar Hybrid Power Plant capacity are in last lag of project and should be commissioned in a quarters time
